Abstract

Urinary tract infection (UTI) due to Escherichia Coli is considered the most commonly acquired bacterial infection in women. Currently used treatments for UTI prevention have conflicting evidence regarding efficacy. There is minimum information regarding the use of Vitamin D and its effect on modulating the innate and adaptive immune system, favoring the production of endogenous antimicrobial peptides such as Cathelicidin. It has been suggested that inducing Cathelicidin in the bladder is a potential complement in preventing UTI. This clinical trial aims at testing the use of Vitamin D in women diagnosed with recurrent UTI due to Escherichia Coli for its prevention. This will be a randomized, double blind controlled trial, with a multicenter approach.
Key-Words: Urinary Tract Infection (UTI); Women; Prophylactic Antibiotic; Vitamin D; Placebo.